Amy Schulman Biography

Amy is a managing partner in the New York office of Polaris Partners and focuses on investments in healthcare companies.

She currently serves as executive chair of SQZ Biotech, as well as Lyndra Therapeutics, where she was co-founder and the company’s initial CEO. She also represents Polaris as a director of Cyclerion (NASDAQ: CYCN), DewPoint Therapeutics, Kallyope, and Volastra. Amy joined Polaris in 2014, at which time she assumed the role of CEO of Arsia Therapeutics, a Polaris-backed company later acquired by Eagle Pharmaceuticals. She also manages the LS Polaris Innovation Fund which was formed in 2017.

Prior to joining Polaris, Schulman was the general counsel of Pfizer, president of Pfizer Nutrition, and was instrumental in its sale to Nestle for $11.85 billion in 2012. Soon after, Schulman became the president of Pfizer Consumer Healthcare.

Schulman has received numerous awards including Xconomy’s 2017 Newcomer Award, Scientific American’s 2015 Worldview 100 List, Fierce Biotech’s 2014 Top 15 Women in Biotech, and Fortune Magazine’s 2013 50 Most Powerful Women in Business. She is a Senior Lecturer at Harvard Business School and serves on the Board of Directors of Alnylam Pharmaceuticals (NASDAQ: ALNY).

She is a Phi Beta Kappa graduate of Wesleyan University and earned her J.D. from Yale Law School.

As a renowned expert and highly sought-after speaker, Amy Schulman's expertise is in high demand. To book Amy Schulman for your next event, conference, or workshop, please contact our speaker booking agency. Our experienced team will work closely with you to understand your specific needs and help secure Amy Schulman's participation. With our professional guidance and seamless booking process, you can ensure a memorable and impactful experience for your audience. Don't miss the opportunity to engage your audience with Amy Schulman's compelling insights and inspire positive change within your organization. Fill out the booking request form to take the first step in securing Amy Schulman for your next speaking engagement.